Antibodies, pharmaceutical compositions and methods

An antibody, or antigen-binding fragment thereof, comprising:

• a heavy chain and a light chain, wherein the heavy chain comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 13, 15 or 17.

An antibody, or antigen-binding fragment thereof, comprising:

• a light chain and a heavy chain, wherein the light chain region comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 6, 8 or 10.

An antibody, or an antigen-binding fragment thereof, produced by the hybridoma designated as Ms deposited under ATCC Accession Number PTA-122679.

A hybridoma designated as Ms deposited under ATCC Accession Number PTA-122679.

An antibody, or an antigen-binding fragment thereof, comprising:

• a heavy chain variable domain (VH) comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence set forth in SEQ ID NO:
• 21 and/or a light chain variable domain (VL) comprising an amino acid sequence of at least about 80% homology to the amino acid sequence as set forth in SEQ ID NO:
• 22.

An antibody, or antigen-binding fragment thereof, comprising:

• a heavy chain and a light chain, wherein the heavy chain comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 31, 33 or 35.

An antibody, or antigen-binding fragment thereof, comprising:

• a light chain and a heavy chain, wherein the light comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 24, 26 or 28.

An antibody, or an antigen-binding fragment thereof, produced by the hybridoma designated as 1Gls deposited under ATCC Accession Number PTA-122678.

A hybridoma designated as 1Gls deposited under ATCC Accession Number PTA-122678.

An antibody, or an antigen-binding fragment thereof, comprising:

• a heavy chain variable domain (VH) comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence set forth in SEQ ID NO:
• 39 and/or a light chain variable domain (VL) comprising an amino acid sequence of at least about 80% homology to the amino acid sequence as set forth in SEQ ID NO:
• 40.

An antibody, or antigen-binding fragment thereof, comprising:

• a heavy chain and a light chain, wherein the heavy chain comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 49, 51 or 53.

An antibody, or antigen-binding fragment thereof, comprising:

• a light chain and a heavy chain, wherein the light chain comprises a complementarity determining region (CDR) amino acid sequence of at least about 80% homology to the amino acid sequence selected from SEQ ID NOs:
• 42, 44 or 46.

An antibody, or an antigen-binding fragment thereof, produced by the hybridoma designated as 2F20s deposited under ATCC Accession Number PTA-122676.

A hybridoma designated as 2F20s deposited under ATCC Accession Number PTA-122676.

An antibody or binding fragment thereof, wherein the antibody or binding fragment thereof comprises VH selected from SEQ ID No:

• 3, SEQ ID No:21, or SEQ ID No:39 and VL selected from SEQ ID No:
• 4, SEQ ID No:22 or SEQ ID No:40.

An antibody-drug conjugate (ADC) comprising a therapeutic agent and an antibody or an antigen-binding fragment that binds SSEA-4, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.